Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779908 | 0.82 | CNR1 (0.44) | CNR1CCR2LMNATRPV4MCL1 | |
| SCHEMBL2371055 | 0.81 | CA12 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL4185547 | 0.78 | L3MBTL1 (0.61) | CA12CA1CA2CA9CNR1 | |
| SCHEMBL2372705 | 0.77 | MCL1 (0.62) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3763976 | 0.76 | PGR (0.55) | LMNAMCL1 | |
| SCHEMBL11512510 | 0.76 | MCL1 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL26567167 | 0.76 | CA12 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11512517 | 0.76 | MCL1 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL10773897 | 0.75 | CA12 (0.47) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3776806 | 0.75 | CA1 (0.45) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7371739-B2 | Aryl fructose-1,6-bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1265907-B9 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1265907-B1 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1607401-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | Metabasis Therapeutics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | CA12 2664/4885CA1 2648/4885CA2 974/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | CA12 2664/4885CA1 2648/4885CA2 974/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | CA12 4591/4885CA1 4224/4885CA2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.